Chromeno[3,4-c]pyridin-5-ones: Selective Human Dopamine D4 Receptor Antagonists as Potential Antipsychotic Agents
Citations Over Time
Abstract
The discovery of a series of chromeno[3,4-c]pyridin-5-ones with selective affinity for the dopamine D4 receptor is described. Target compounds were tested for binding to cloned human dopamine D2, D3, and D4 receptor subtypes expressed in Chinese hamster ovary (CHO) K-1 cells. Several compounds demonstrated single digit nanomolar Ki values for binding to the D4 receptor with several hundred-fold selectivities toward the D2 and D3 receptors. A limited SAR study of this series is discussed. In a mitogenesis assay measuring [3H]thymidine uptake, the target compounds showed antagonist to weak partial agonist activity at the D4 receptor, with intrinsic activities ranging from 0 to 35%. Compound 6, 3-benzyl-8-methyl-1,2,3,4-tetrahydrochromeno[3,4-c]pyridin-5-one, increased DOPA (L-3,4-dihydroxyphenylalanine) synthesis 84% in the hippocampus and 10% in the striatum of rat brain when dosed orally at 10 mg/kg.
Related Papers
- → In Vitro and In Vivo Identification of Novel Positive Allosteric Modulators of the Human Dopamine D2 and D3 Receptor(2015)26 cited
- → Effects of repeated treatment with the dopamine D2/D3 receptor partial agonist aripiprazole on striatal D2/D3 receptor availability in monkeys(2013)6 cited
- → P.4.13 The D2/D3 dopamine receptor partial agonist aripiprazole attenuates cue-induced cocaine relapse in rats(2009)1 cited
- → P2.104 Effects of pardoprunox (SLV308), a partial D2/D3 receptor and 5-HT1A receptor agonist, on rat dopamine and serotonin neuronal activity(2009)
- → Dopamine D2/3 receptor partial agonists failed to produce antidepressant‐like effects in the rat forced swim test(2009)